Congratulations to Irem Dagliyan for successfully passing her doctoral defense! Irem presented Low dose vertical inhibition of ERK MAPK cascade for the treatment of KRAS-mutant cancer in 4007 Genetic Medicine Building. Afterword, she celebrated her success with her labmates, friends, and family. We are excited for Irem to begin her new journey as Dr. Irem Dagliyan! … Continue reading Congratulations, Dr. Irem Dagliyan!
August 5, 2019 Today, the Der and Cox labs were visited by the Blue Ribbon group of Wilmington, NC. The Blue Ribbon Run raises money for the Julie M. Brown and Christina M. Gianoplus Fund for Colon Cancer Research from Wilmington, NC. Members of the group included Ana Boudreau, event founder, and Sarah Powell, a … Continue reading Der Lab Blue Ribbon Tour 2019
Nate Diehl was awarded an NCI F30 Individual Predoctoral MD/Ph.D. fellowship entitled “Validation of WEE1 kinase as a clinical target in KRAS-mutant pancreatic cancer”. Jenny Klomp, Ph.D., was awarded an NCI F32 Individual Postdoctoral fellowship entitled “Defining the roles of the ERK MAPK in driving KRAS-mutant pancreatic cancer growth”. Congratulations to you both!
This summer, the Der, Cox, Campbell, and Counter labs visited Emerald Isle, NC. Together they spent three days giving talks, getting to know one another, and discussing upcoming projects.
https://www.youtube.com/watch?v=Nc-uE0Dzff0&feature=youtu.be Dr. John Marshall hosted a panel at the 2018 Ruesch Center Annual Symposium focused on tumor targets. Panel guests were Dr. Eric Collisson, Dr. Channing Der, and Dr. Michael Korn. Dr. Eric Collisson discusses the emergence in oncology of a new class of drugs called PARP inhibitors. These have been more commonly used in … Continue reading Tumor Targets Panel– Ruesch Center Annual Symposium 2018
In the journal Cancer Cell, UNC Lineberger's Channing Der, PhD, and colleagues described how pancreatic cancer may develop resistance to ERK inhibitors in pancreatic cancer. November 16, 2018 Despite decades of research, treatments that can target a common mutation in the most frequently diagnosed type of pancreatic cancer have remained elusive. Now, University of North … Continue reading UNC Lineberger Writes: Researchers identify resistance mechanism to possible pancreatic cancer treatment
UNC's Running RAScals (aka the Der Lab at UNC Lineberger & Friends) participated in this year’s PanCAN #PurpleStride run on Saturday, April 21st. This 5k run raises money to support the Pancreatic Cancer Action Network. The team, organized by Kirsten Bryant, raised $10,839 to support Pancreatic Cancer Research, coming in Fifth in overall fundraising! This was the Der Lab's fifth … Continue reading PurpleStride Raleigh-Durham 2018: Running RAScals
Rick and Donna Martinez have a morning live interview show featuring conversations with community personalities and leaders about issues that impact you. We are happy to share the March 1, 2018 radio podcast with our own Pancreatic Cancer Experts Channing Der, PhD and Kirsten Bryant, PhD. This interview discusses common perceptions of Pancreatic Cancer; Symptoms … Continue reading News radio 680 WPTF on Pancreatic Cancer
This past Saturday several members of the Der Lab participated in the Tar Heel 10 Miler. The Tar Heel 10 Miler benefits the UNC Lineberger Comprehensive Cancer Center and the Chapel Hill-Carrboro YMCA’s We Build People Campaign. The lab runners included postdocs Kirsten Bryant, Clint Stalnecker, Andrew Waters, and Bjoern Papke, graduate student Nate Diehl, and … Continue reading Der Lab Participates in Tar Heel 10 Miler
PurpleStride is the signature event of the Pancreatic Cancer Action Network. Each year, in communities across the country, tens of thousands of people participate in more than fifty-six PurpleStride events, including PurpleStride Raleigh-Durham. These events are critical in raising awareness and funds that advance research and support patients and loved ones with a promise of … Continue reading Photos from Purple Stride 2016